Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and

Pluristem Welcomes Parliamentary State Secretary of the German Federal
Ministry for Environmental, Nature Conservation and Nuclear Safety and the
Chairman of the Charite Berlin-Brandenburg Center for Regenerative Therapies

New Opportunities Discussed to Strengthen Collaborative Relationships Using
Pluristem's Placental Expanded (PLX) Cells

HAIFA, Israel, May 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that Katherina Reiche, Parliamentary State
Secretary of the German Federal Ministry for Environmental, Nature
Conservation and Nuclear Safety, and Prof. Dr. Hans-Dieter Volk, Chairman of
the Charite Berlin-Brandenburg Center for Regenerative Therapies (BCRT),
Berlin Germany, met with Pluristem's management and scientists on May 22,
2013. Meetings were held at the company's new manufacturing and R&D
headquarters in Haifa, Israel to discuss new opportunities to strengthen
existing collaborations Pluristem has with the BCRT and other German clinical
research facilities.

Zami Aberman, Pluristem's Chairman and CEO, stated, "Pluristem has enjoyed a
longstanding relationship with the BCRT, one of Germany's leading
translational research institutions, who has conducted research for several
indications using our PLX cells. We were fortunate that State Secretary Ms.
Reiche and Prof. Dr. Volk were able to visit our new facility and discuss
expanding our existing, valuable association in Germany."

Prof. Volk stated, "The BCRT values the affiliation we have with Pluristem and
look forward expanding this collaboration in the future utilizing their
exciting, innovative PLX technology."

Parliamentary State Secretary Ms. Reiche stated, "PluristemĀ“s collaboration
with BCRT is a path-breaking example of how cutting edge technologies can be
translated into innovative therapies and applications. The intelligent
investment in Germany and Israel into infrastructure, research and products
pays off for the benefit of patients."

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss the
opportunities discussed with the German federal ministry and the Charite
Berlin-Brandenburg Center, to strengthen and expand existing collaborations,
we are using forward-looking statements. These forward-looking statements and
their implications are based on the current expectations of the management of
Pluristem only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching and/or successfully completing
our clinical trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process; our
products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may
harm recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Pluristem undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a
more detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.